PAK1 and ovarian cancer: In ovarian cancer, it suppresses proliferation and epithelial-mesenchymal transition (EMT) via the p21-activated kinase 1 (PAK1)/β-catenin pathway [14], while its knockdown enhances cisplatin sensitivity in ovarian cancer cells by inhibiting proliferation and EMT [15].